

London Cancer Urology Tumour Pathway Board Annual Report 2017-18

Introduction

London Cancer incorporates the geographical areas of North Central and East London and West Essex with a population of 3.7 million. Since 2016, *London Cancer* has become one of the six principal programmes of the UCLH Cancer Collaborative

The Urology Tumour Pathway Board is a cancer care specific board led by Mr John Hines the Tumour Pathway Director. Its membership includes representation from cancer professionals across the region and active participation from primary care and patients.

The role of each pathway board is to understand any variation in practice and set standards that take advantage of planning whole pathways of cancer care for a large population. This drive to improve cancer care for patients covers an integrated care pathway that extends from presentation and diagnosis through to palliative care and living with and beyond cancer

This year saw the pelvic cancer centre at UCLH pass through the final gateway of the assurance process for the reconfiguration of radical pelvic cancer surgery.

Working collaboratively with our vanguard partners has proven to be highly valuable in developing a new timed pathway for prostate cancer patients that will benefit the NHS on a national scale.

Achievements this year

2017/18 has seen the Urology Tumour Pathway board continue working collaboratively with our Vanguard partners in Manchester and London on developing a new best practice timed pathway for Prostate patients. This timed pathway has now been finalised and was discussed at the Communities of Practice event on 8th February 2018 with all Cancer Alliances in England present.

This year we have continued to focus on streamlining the cancer pathways within our network and reducing the variation of care given across the UCLH Cancer Collaborative trusts. There has also been a focus on improving the 62 day performance for Prostate patients across the network.

Our key achievements have been:

- **Inter-trust referral support**

- Producing monthly analysis on Inter-trust referral data and trends for both the prostate and renal cancer pathways.
- Held a workshop for administrative staff working across *London Cancer* to meet and discuss ways in which to improve the pathway.



Mr John Hines, Pathway Board Director, Consultant Urologist at Barts Health/UCLH

UCLH Cancer Collaborative brings together hospital trusts, GPs, health service commissioners, local authorities and patients across north and east London and west Essex.

- **Prostate Diagnostic Improvement**
 - Funded a two day MRI masterclass course for Urologists and Radiologists (September 2017). Funded an RCR multi-parametric MRI course for Radiologists (March 2018).
 - Developed a 'How to Guide' on the establishment of one-stop prostate diagnostic clinics. This how to guide was based on the successful clinic established at Royal Free.
 - Supported the national consensus meeting on the implementation of multi-parametric MRI for prostate cancer detection.
 - Recruited an MRI physicist to support trusts in implementing multi-parametric MRI into their prostate diagnostic pathway.
 - Produced, in collaboration with our patient representatives a prostate pathway patient information leaflet.
- **The specialist pelvic cancer surgery centre at UCLH passed both the gateway 5 and 6 assurance documents.**
- **Updated the bladder cancer guidelines.**
- **The Stratified Care of patients with prostate cancer in the Community (SCC)** is an NHSE national target. The Urology Pathway Board SCC sub-group spent 2 years working on the possible models to deliver this plan. North Central London (NCL) decided to adopt a primary care-led model and North East London chose a remote secondary care-led model, although this may evolve into a primary care model. The NCL pathway began in October 2017 and, so far, no patient has reached the first 'node', a PSA test one year after starting the pathway. The NCL pathway is supported by a prospective audit run by London Cancer.

Patient representation

Our patient representatives have continued to be a vital part of each pathway board meeting. This year we have worked with our patient representatives to establish a new patient information leaflet which has now been implemented at both UCLH and Bart Health. We are working with all trusts within our network to implement the use of this leaflet.

Future plans

In 2018/19 we will continue to build on our work streams from the previous year. Our work plan is outlined below.

No	Objective	Owner	By
1	Continue the initiatives set out in 17/18 to improve 62 day performance across the network.	JH	March 19
2	Support the roll out of the new pan vanguard prostate timed pathway.	JH	December 18
3	Continue to reduce variation and improve MRI standards across the network.	SP/CM	March 19
4	Update the Renal and Prostate clinical guidelines	JH/RB	September 18

Acknowledgements

We would like to thank all the members of the Urology Tumour Pathway Board for contributing their time to Tumour Pathway Board meetings and projects outside the meeting.

Particular thanks to our patient representatives Veronica Brinton, John Sandell and Jane Smith who have generously given up their time to contribute.